← All trials
NCT04836494
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 25, 2021
- Primary completion
- Jul 28, 2022
- Completion date
- Jul 28, 2022
- First posted
- Apr 8, 2021
- Last posted
- Sep 14, 2021
- Enrollment
- 128
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bridge BioResearch Ltd.Lead sponsor
- Bridge Biotherapeutics, Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.